來源:[1] Guardant 報告 Shield 演算法臨床讀數更新 (https://www.medicaldevice-network.com/news/gu ...)[2] 儘管 Evercore ISI 持積極展望,Guardant Health 股價仍下跌 8% - Investing.com (https://vertexaisearch.cloud.google.com/groun ...)[3] Guardant Health 的 Shield 血液檢測顯示對結直腸癌有 84% 的靈敏度 - Investing.com (https://www.investing.com/news/stock-market-n ...)